Company: TELO
Filing Date: 2025-05-29
Form Type: 8-K
Source: 0001641172-25-012785
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-29
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using
FDA-Recognized Surrogate Endpoints

On
May 29, 2025, Telomir Pharmaceuticals, Inc. (the “ Company”) announced new preclinical data from its ongoing development of
Telomir-1, an investigational oral small molecule candidate being developed for the treatment of age-related macular degeneration (“ AMD”).

The
study was conducted using the Sen57wrn-/-ND6-/+ zebrafish model, which incorporates genetic mutations associated with premature aging
(WRN), mitochondrial dysfunction (ND6), and chronic senescence (Sen57). This model mimics key features of dry AMD and geographic atrophy
observed in human disease.

Eighteen-month-old
animals were administered Telomir-1 orally for a period of 14 days. The following outcomes were observed:

  Functional                                                                                     
  Retinal                                                                                        
  Reduction                                                                                      
  Survival                                                                                       

The
Company believes these results represent a significant preclinical milestone, demonstrating that Telomir-1, administered orally, can
restore vision-related function, regenerate damaged retinal tissue, reduce oxidative stress, and improve survival in a validated model
of AMD. The study utilized endpoints consistent with FDA-recognized surrogate markers for visual function, supporting continued advancement
of Telomir-1 toward Investigational New Drug (IND) submission.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    TELOMIR                                       
  Dated:            By:                        /s/                
                    Name:                      Erez               
                    Title:                     Chief